A Phase 2, 12-Week, Randomized, Double-Blind, Placebo-Controlled Study of DS-1211b in Individuals with Pseudoxanthoma Elasticum
Latest Information Update: 06 Jan 2025
At a glance
- Drugs DS-1211 (Primary)
- Indications Pseudoxanthoma elasticum
- Focus Adverse reactions; Pharmacodynamics
- Sponsors Daiichi Sankyo Inc
Most Recent Events
- 13 Jun 2024 Status changed from active, no longer recruiting to completed.
- 17 Dec 2023 This trial has been completed in Netherland, according to European Clinical Trials Database record (2023-11-21).
- 02 Oct 2023 Planned End Date changed from 29 Sep 2023 to 1 Apr 2024.